AKTS
Aktis Oncology, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-26/100
Last price
17.86
▼ 0.66 (3.56%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
18.52
Day high
18.75
Day low
17.81
Volume
294.76K
Market cap
$993.36M
P/E (TTM)
—
52W range
14.72 – 34.19
Trailing performance
Returnvs SPY
1W
-9.29%
-11.2%
1M
-33.97%
-35.1%
3M
-37.75%
-42.3%
6M
+6.82%
-11.4%
YTD
-20.27%
-34.5%
1Y
—
-16.4%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on AKTS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
5
120.42K shares
Sell transactions
5
120.42K shares
Net transactions
+10
Buys less sells
Sell : buy shares
1.0 : 1
Mixed
Insider-held shares
7.82M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 23, 26 | CZIBERE AKOS M.D. Officer |
CONVERSION | 12.50K | $61.88K | Direct |
| Sep 23, 26 | CZIBERE AKOS M.D. Officer |
SELL | 12.50K | $258.62K | Direct |
| Jul 20, 26 | HERRMANN KEN M.D. Director |
CONVERSION | 4.86K | $2.86K | Direct |
| Jul 20, 26 | HERRMANN KEN M.D. Director |
SELL | 4.86K | $119.27K | Direct |
| Jul 17, 26 | HERRMANN KEN M.D. Director |
CONVERSION | 3.06K | $245 | Direct |
| Jul 17, 26 | HERRMANN KEN M.D. Director |
SELL | 3.06K | $77.26K | Direct |
| Jul 8, 26 | RON-BIGGER SHULAMIT PH.D. Chief Operating Officer |
CONVERSION | 50.00K | $183.00K | Direct |
| Jul 8, 26 | CZIBERE AKOS M.D. Officer |
CONVERSION | 50.00K | $247.50K | Direct |
| Jul 8, 26 | RON-BIGGER SHULAMIT PH.D. Chief Operating Officer |
SELL | 50.00K | $1.39M | Direct |
| Jul 8, 26 | CZIBERE AKOS M.D. Officer |
SELL | 50.00K | $1.39M | Direct |
| Jan 12, 26 | GADICKE ANSBERT S. Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.11M | $20.03M | Indirect |
| Jan 12, 26 | FOLEY TODD Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 232.87K | $4.19M | Indirect |
| Jan 12, 26 | KIM HELEN SUSAN Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 835.00K | $15.03M | Indirect |
| Jan 12, 26 | MPM BIOVENTURES 2018, L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.11M | $20.03M | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CZIBERE AKOS M.D. |
Officer | 0 | Conversion of Exercise of derivative security |
ECOR1 CAPITAL, L.L.C. |
Unknown | — | Purchase |
FOLEY TODD |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
GADICKE ANSBERT S. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
HERRMANN KEN M.D. |
Director | 0 | Conversion of Exercise of derivative security |
KIM HELEN SUSAN |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
MPM BIOVENTURES 2018, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
RON-BIGGER SHULAMIT PH.D. |
Chief Operating Officer | 0 | Conversion of Exercise of derivative security |
SEGAL LLOYD MITCHELL |
Director | — | Conversion of Exercise of derivative security |
VIDA VENTURES II, L.L.C |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
Fundamentals
Market cap$993.36M
Enterprise value$487.28M
Revenue (TTM)$10.06M
Gross profit$-68.22M
EBITDA$-84.36M
Net income$-73.14M
EPS (TTM)$-1.70
Free cash flow—
Total cash$517.32M
Total debt$11.24M
Book value / share$8.76
Shares outstanding53.75M
Float28.59M
Short % of float20.12%
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-8.32
PEG ratio—
Price / sales—
Price / book2.04
EV / revenue48.44
EV / EBITDA-5.78
Gross margin0.00%
Operating margin-853.99%
Profit margin0.00%
Return on equity—
Return on assets—
Debt / equity2.32
Current ratio16.33
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $6.50M | $1.49M | $0 | $0 | +336.9% |
| Operating revenue | $6.50M | $1.49M | $0 | $0 | +336.9% |
| Research & development | $67.45M | $40.95M | $25.92M | $14.30M | +64.7% |
| Selling, general & admin | $12.60M | $11.31M | $7.68M | $5.11M | +11.4% |
| Total operating expense | $81.18M | $53.54M | $34.79M | $19.76M | +51.6% |
| Operating income | -$74.68M | -$52.05M | -$34.79M | -$19.76M | -43.5% |
| Net interest income | $11.01M | $8.10M | $5.38M | $1.65M | +35.9% |
| Pre-tax income | -$63.73M | -$43.98M | -$28.64M | -$17.93M | -44.9% |
| Net income | -$63.73M | -$43.98M | -$28.64M | -$17.93M | -44.9% |
| Net income to common | -$63.73M | -$43.98M | -$28.64M | -$17.93M | -44.9% |
| Basic EPS | -1.21 | -1.26 | -0.82 | -0.51 | +3.8% |
| Diluted EPS | -1.21 | -1.26 | -0.82 | -0.51 | +3.8% |
| EBIT | -$74.68M | -$52.05M | -$34.79M | -$19.76M | -43.5% |
| EBITDA | -$72.36M | -$50.48M | -$33.60M | -$19.32M | -43.3% |
| Basic shares | 52.52M | 34.86M | 34.86M | 34.86M | +50.6% |
| Diluted shares | 52.52M | 34.86M | 34.86M | 34.86M | +50.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $37.78M | $37.16M | $29.51M | $128.60M | +1.7% |
| Cash & short-term investments | $226.79M | $297.17M | $97.86M | $128.60M | -23.7% |
| Total current assets | $230.31M | $300.85M | $100.20M | $132.48M | -23.4% |
| Property, plant & equipment | $27.25M | $20.87M | $20.92M | $4.87M | +30.5% |
| Total assets | $264.88M | $326.18M | $122.36M | $138.32M | -18.8% |
| Total current liabilities | $31.24M | $18.82M | $6.24M | $5.28M | +66.0% |
| Total debt | $11.55M | $12.01M | $13.40M | $1.77M | -3.8% |
| Total liabilities | $411.03M | $413.98M | $168.66M | $157.55M | -0.7% |
| Retained earnings | -$156.56M | -$92.83M | -$48.85M | -$20.21M | -68.7% |
| Shareholder equity | -$146.15M | -$87.80M | -$46.31M | -$19.23M | -66.5% |
| Working capital | $199.07M | $282.03M | $93.97M | $127.21M | -29.4% |
| Net tangible assets | -$146.15M | -$87.80M | -$46.31M | -$19.23M | -66.5% |
| Shares issued | 52.52M | 52.52M | 52.52M | 52.52M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$63.73M | -$43.98M | -$28.64M | -$17.93M | -44.9% |
| Depreciation & amortisation | $2.33M | $1.57M | $1.12M | $445.00K | +47.9% |
| Stock-based compensation | $5.13M | $2.26M | $1.48M | $698.00K | +127.0% |
| Change in working capital | -$3.23M | $58.98M | -$15.00K | -$1.14M | -105.5% |
| Operating cash flow | -$64.13M | $14.76M | -$30.00M | -$18.13M | -534.4% |
| Capital expenditure | -$9.58M | -$2.86M | -$3.76M | -$2.31M | -234.9% |
| Investing cash flow | $65.96M | -$190.40M | -$68.83M | -$2.31M | +134.6% |
| Financing cash flow | -$1.21M | $183.28M | $0 | $119.98M | -100.7% |
| Free cash flow | -$73.71M | $11.90M | -$33.77M | -$20.43M | -719.4% |
| End cash position | $38.93M | $38.31M | $30.66M | $129.49M | +1.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $3.38M | $3.23M | $1.87M | $1.58M | $1.60M | — | +4.9% |
| Operating revenue | $3.38M | $3.23M | $1.87M | $1.58M | $1.60M | — | +4.9% |
| Research & development | $25.28M | $20.04M | $16.49M | $16.47M | $18.63M | — | +26.2% |
| Selling, general & admin | $6.40M | $5.34M | $2.51M | $3.06M | $3.68M | — | +19.9% |
| Total operating expense | $32.28M | $25.93M | $19.25M | $19.78M | $22.56M | — | +24.5% |
| Operating income | -$28.90M | -$22.71M | -$17.38M | -$18.20M | -$20.96M | — | -27.3% |
| Net interest income | $4.76M | $4.38M | $2.25M | $2.68M | $2.91M | — | +8.7% |
| Pre-tax income | -$24.14M | -$18.32M | -$15.14M | -$15.53M | -$18.07M | — | -31.8% |
| Net income | -$24.14M | -$18.32M | -$15.14M | -$15.53M | -$18.07M | — | -31.8% |
| Net income to common | -$24.14M | -$18.32M | -$15.14M | -$15.53M | -$18.07M | — | -31.8% |
| Basic EPS | -0.44 | -0.38 | — | — | -0.34 | -0.43 | -14.9% |
| Diluted EPS | -0.44 | -0.38 | — | — | -0.34 | -0.43 | -14.9% |
| EBIT | -$28.90M | -$22.71M | -$17.38M | -$18.20M | -$20.96M | — | -27.3% |
| EBITDA | -$28.02M | -$22.05M | -$16.68M | -$17.61M | -$20.41M | — | -27.1% |
| Basic shares | 55.32M | 48.63M | — | — | 52.52M | 34.86M | +13.8% |
| Diluted shares | 55.32M | 48.63M | — | — | 52.52M | 34.86M | +13.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $82.49M | $371.63M | $37.78M | $180.25M | -77.8% |
| Cash & short-term investments | $517.32M | $538.48M | $226.79M | $246.22M | -3.9% |
| Total current assets | $524.54M | $543.94M | $230.31M | $249.42M | -3.6% |
| Property, plant & equipment | $28.20M | $28.11M | $27.25M | $24.30M | +0.3% |
| Total assets | $557.60M | $576.80M | $264.88M | $279.04M | -3.3% |
| Total current liabilities | $32.13M | $27.91M | $31.24M | $26.91M | +15.1% |
| Total debt | $11.24M | $11.58M | $11.55M | $11.87M | -2.9% |
| Total liabilities | $72.76M | $70.69M | $411.03M | $411.43M | +2.9% |
| Retained earnings | -$199.03M | -$174.89M | -$156.56M | -$141.43M | -13.8% |
| Shareholder equity | $484.84M | $506.11M | -$146.15M | -$132.39M | -4.2% |
| Working capital | $492.41M | $516.03M | $199.07M | $222.51M | -4.6% |
| Net tangible assets | $484.84M | $506.11M | -$146.15M | -$132.39M | -4.2% |
| Shares issued | 55.32M | 55.28M | 52.52M | 52.52M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$24.14M | -$18.32M | -$15.14M | -$15.53M | -$18.07M | -31.8% |
| Depreciation & amortisation | $879.00K | $652.00K | $695.00K | $598.00K | $552.00K | +34.8% |
| Stock-based compensation | $3.22M | $3.02M | $1.10M | $1.28M | $1.52M | +6.6% |
| Change in working capital | $489.00K | -$9.06M | -$1.19M | -$820.00K | $1.14M | +105.4% |
| Operating cash flow | -$20.59M | -$24.24M | -$15.24M | -$15.22M | -$16.18M | +15.1% |
| Capital expenditure | -$1.26M | -$1.85M | -$4.15M | -$2.00M | -$1.53M | +31.9% |
| Investing cash flow | -$268.71M | $20.54M | -$126.46M | $85.23M | $68.14M | -1,408.2% |
| Financing cash flow | $156.00K | $337.55M | -$772.00K | $28.00K | $0 | -100.0% |
| Free cash flow | -$21.85M | -$26.10M | -$19.39M | -$17.23M | -$17.71M | +16.3% |
| End cash position | $83.64M | $372.78M | $38.93M | $181.40M | $111.36M | -77.6% |
Options analytics
Put / call volume
1.14
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
17.50
-2.0% from spot
ATM implied vol
25.0%
Nearest strike to spot
Skew (10% OTM)
-21.9%
Calls bid over puts
Call volume
14
Contracts, this expiry
Put volume
16
Contracts, this expiry
Heaviest call OI
22.50
0 contracts
Heaviest put OI
17.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.43 | -0.44 | -2.2% |
| Mar 2026 | -0.33 | -0.38 | -15.2% |
| Dec 2025 | -1.15 | — | — |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.46 | 7 | $2.33M | — |
| Next quarter | -0.48 | 7 | $2.13M | +13.8% |
| Current year | -1.69 | 8 | $10.25M | +57.7% |
| Next year | -2.15 | 8 | $9.67M | -5.7% |
Analyst targets & ownership
Mean target$35.39
High target$40.00
Low target$31.50
Implied upside98.15%
Analyst count9
ConsensusSTRONG BUY
Strong buy / Buy1 / 9
Hold0
Sell / Strong sell0 / 0
Held by insiders14.05%
Held by institutions72.98%
Institutions holding163
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
19.07
-6.35% from price
SMA 20
20.93
-14.66% from price
SMA 50
23.15
-22.84% from price
SMA 100
23.38
-23.60% from price
SMA 200
—
—
EMA 12
19.61
-8.92% from price
EMA 26
21.24
-15.93% from price
EMA 50
22.42
-20.33% from price
RSI (14)
23.9
Oversold
MACD (12,26,9)
-1.63
Hist -0.24
ATR (14)
1.09
6.12% of price
Realised vol 30D
49.0%
Annualised
Bollinger upper
24.92
20, 2σ
Bollinger lower
16.94
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.51
More volatile than market
Correlation to SPY
0.29
Largely independent
Realised vol 30D
49.0%
Annualised
Market vol 1Y
13.2%
SPY, annualised
Max drawdown 1Y
-44.6%
Peak to trough
Max drawdown 5Y
-44.6%
Peak to trough
ATR 14
1.09
6.12% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
3.25M
Prior 3.45M
Change vs prior
-5.6%
Shorts covering
% of float
20.12%
Heavily shorted
% of shares out
5.85%
Against total outstanding
Days to cover
10.9
Crowded exit
Float
28.59M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Sep 9, 26 | Oppenheimer | INITIATED | — | Outperform |
| Aug 19, 26 | Wedbush | INITIATED | — | Outperform |
| Aug 19, 26 | BMO Capital | INITIATED | — | Outperform |
| Jul 14, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Jun 16, 26 | Raymond James | INITIATED | — | Strong Buy |
| Jun 2, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 29, 26 | William Blair | INITIATED | — | Outperform |
| Mar 31, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 9, 26 | HC Wainwright & Co. | INITIATED | — | Buy |
| Feb 3, 26 | Leerink Partners | INITIATED | — | Outperform |
| Feb 3, 26 | JP Morgan | INITIATED | — | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-05-11
Corporate Changes & Voting Matters
8-K · 2026-04-16
Corporate Changes & Voting Matters
8-K · 2026-03-31
Periodic Financial Reports
10-K · 2026-03-30
Corporate Changes & Voting Matters
8-K · 2026-01-12
Trading Registrations
8-A12B · 2026-01-07
Offering Registrations
S-1/A · 2026-01-05
Headlines
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
GlobeNewswire · 6d ago
Oppenheimer Initiates Coverage on Akoustis Technologies With Outperform Rating, $40 PT
MT Newswires · 28d ago
Aktis Oncology to Present at Upcoming September Investor Conferences
GlobeNewswire · 28d ago
Aktis Oncology Seen Advancing Targeted Radiation-Based Cancer Drugs, Wedbush Says
MT Newswires · 49d ago
Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play
24/7 Wall St. · 49d ago
Wedbush Initiates Aktis Oncology at Outperform With $35 Price Target
MT Newswires · 49d ago
Aktis: Q2 Earnings Snapshot
Associated Press · 55d ago
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
GlobeNewswire · 55d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.